Thumbnail
Access Restriction
Subscribed

Author Leroux Roels, Geert
Source SpringerLink
Content type Text
Publisher Springer Berlin Heidelberg
File Format PDF
Copyright Year ©2014
Language English
Subject Domain (in DDC) Technology ♦ Medicine & health
Subject Keyword Hepatitis B virus ♦ Vaccine ♦ Adjuvant ♦ Adjuvant systems ♦ Prophylaxis ♦ Medical Microbiology ♦ Immunology
Abstract The safety and immunogenicity profiles of currently available recombinant hepatitis B vaccines are excellent. However, it remains a real challenge to induce protective immunity in the target groups that respond poorly or not at all to conventional vaccines. Ideally, a hepatitis B vaccine can be developed that conveys lifelong protection against infection rapidly after the injection of a single dose. Although this goal is far from being reached, important improvements have been made. Novel vaccine adjuvants have been developed that enhance the immunogenicity of recombinant hepatitis B vaccines while maintaining a good safety profile. The different adjuvants and adjuvant systems that are discussed herein have all been thoroughly evaluated in clinical trials and some have reached or are close to reach the market.
ISSN 03008584
Age Range 18 to 22 years ♦ above 22 year
Educational Use Research
Education Level UG and PG
Learning Resource Type Article
Publisher Date 2014-12-19
Publisher Place Berlin/Heidelberg
e-ISSN 14321831
Journal Medical Microbiology and Immunology
Volume Number 204
Issue Number 1
Page Count 10
Starting Page 69
Ending Page 78


Open content in new tab

   Open content in new tab
Source: SpringerLink